Verve Therapeutics, Inc.VERV

時価総額

$3.4億

PER

	2021年 12月31日	2022年 12月31日
Net loss	-120	-157
Depreciation	2	3
Non-cash lease expense	2	4
Net amortization of premium (accretion of discount) on marketable securities	-	-1
Stock-based compensation	7	22
Change in fair value of antidilution rights	26	-
Change in fair value of success payments liabilities	8	-1
Collaboration receivable	-	1
Prepaid expenses and other current assets	8	9
Accounts payable	7	-5
Accrued expenses and other liabilities	6	7
Success of payment liability	-6	-
Deferred revenue	-	20
Operating lease liabilities	-2	-3
Net cash used in operating activities	-78	-122
Purchases of property and equipment	4	13
Purchases of marketable securities	371	479
Maturities of marketable securities	137	337
Net cash used in investing activities	-239	-156
Proceeds from issuance of Preferred Stock, net	94	-
Proceeds from Issuance Initial Public Offering	285	-
Proceeds from Issuance of Common Stock	-	40
Proceeds from issuance of common shares, net of commissions	-	287
Payment of equity offering costs	-	1
Proceeds from Stock Options Exercised	1	2
Employee Stock Ownership Plan (ESOP), Cash Contributions to ESOP	1	1
Net cash provided by financing activities	377	329
Increase (decrease) in cash, cash equivalents and restricted cash	60	51
Property and equipment additions included in accounts payable and accrued expenses	1	2
Conversion of convertible preferred stock to common stock upon closing of initial public offering	219	-
Settlement of derivative liability by issuing common stock	32	-
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability	1	83